This is a great article. If you'd like a good summary of the company's history, its product, and the present controversy surrounding the high price of Acthar, this is it.http://www.nytimes.com/2012/12/30/business/questcor-finds-pr...If the article is true, I did not realize the extent to which Questcor will ensure that their expensive drug gets to those who need it. Ultimately, the entity that pays the high price is the insurer. This is not a company that is bleeding individuals dry.One other thing that struck me again is how solid Questcor's moat is surrounding Acthar. If other companies want to bring a similar drug to the market, they will need to run the whole gambit to get theirs approved in the United States...even Synacthen, which is approved in Europe. That will take a long time and maybe is not even worth the cost.Carl
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra